Clinical trial results of first Russian quadrivalent influenza vaccine presented at the Sixth ESWI Influenza Conference
Petrovax Pharm shared clinical trial results of the first Russian quadrivalent influenza vaccine at the Sixth ESWI Influenza Conference held in Riga on 10–13 September 2017.
The Sixth ESWI Influenza Conference is the largest European scientific conference on influenza hosted by the European Scientific Working group on Influenza once every three years. The international conference is attended by renowned scientists and leading influenza and immunization experts from all over the world. This year, the conference addressed burning issues concerning influenza, new health threats, and pandemics as well as reviewed the latest developments in epidemiological surveillance and vaccination, showcased achievements, and shared prospects for preventing this dangerous disease.
Petrovax Pharm took an active part in the conference along with the world's leading manufacturers of vaccines and antiviral medicines. On 12 September, within the framework of the scientific symposium “A New Generation of Influenza Vaccines: the Future of Influenza Vaccination”, Marina Abramova, Petrovax Pharm’s Vice President for R&D, presented clinical trial results for Grippol® Quadrivalent, the first Russian quadrivalent influenza vaccine. She also shared the details of the development and use of the Grippol family of adjuvanted subunit inactivated influenza vaccines.
“Grippol® Quadrivalent is the most advanced influenza vaccine on the world scale. It boasts high preventive efficacy and safety, and protects against four influenza strains at a time,” noted Marina Abramova. “The vaccine contains Polyoxidonium, an immunoadjuvant that contributes to the development of a persistent immune response and ensures high safety profile. The vaccine will be manufactured in Russia based on a full-cycle technology starting from the API production. Clinical studies in adults have been successfully completed; the efficacy and safety of Grippol® Quadrivalent as well as its compliance with EMA CPMP international criteria have been confirmed,” said Marina Abramova. Currently, documents have been filed with the Russian Ministry of Health to obtain marketing authorization. In 2018, the vaccine will be launched to the Russian market. Potential annual output will be 40M m doses.
Since 2012, the WHO has issued quadrivalent influenza vaccine guidelines. Currently, only five countries in the world manufacture quadrivalent vaccines, namely Australia, USA, Canada, Germany, and France. Russia will be the sixth country to independently manufacture such vaccines.